GKOS: Bull Flag detected on 20 Jul 2026

Glaukos is establishing a bull flag pattern following record Q1 2026 results (net sales up 41% YoY to $150.6M, glaucoma sales up 47% YoY). The pattern shows a consolidation near resistance at $156.60, with the current price at $156.83 just above this level. Structure scores 15.0/15, volume at 11.4/12, and breakout at 11.0/13 reflect a high-quality setup. Support sits at $146.72, offering a 6.5% cushion. The bull flag follows a 45-day ascending triangle that formed in May, combining to reinforce upside momentum. RSI at 69.5 signals strength without extreme overbought conditions.

Glaukos raised full-year 2026 revenue guidance to $620-635M following strong Q1 results on April 29. iDose® TR, a first-of-its-kind intracameral procedural pharmaceutical launched in 2024, is driving differentiated growth. Gross margins improved to 78% GAAP and 84% non-GAAP in Q1, demonstrating operational leverage. The company completed enrollment in a Phase 2 study for GLK-321 addressing Demodex blepharitis, expanding its pipeline. Q2 2026 earnings are scheduled for July 29, 2026—nine days from pattern detection. The earnings catalyst nine days away creates a potential near-term volatility inflection point that could either accelerate the breakout or force a sharp pullback.

A successful breakout from this bull flag would target $162.01 (conservative measured move), representing a 3.3% upside from current levels. Volume confirmation is critical—current volume at 375K shares trails the 20-day average of 838K, so a decisive breakout would require volume expansion above 600K to validate conviction. The invalidation level sits at support (146.72), a break below which would signal pattern failure. The 75.13% win probability indicates historical precedent for this setup; past similar bull flags showed breakouts succeeding roughly three times out of four. Time decay favors quick resolution given the imminent July 29 earnings date.

Q2 earnings on July 29, 2026 represent the primary catalyst event—just nine days away. Beta of 1.62 means GKOS carries significant magnified volatility versus the broader market; adverse earnings surprises or guidance cuts could trigger outsized downside. RSI at 69.5 sits in the upper range, leaving limited room for momentum-driven gains before potential pullback. Volume is depressed (relative volume 0.45x average), meaning thin liquidity could amplify price moves on large institutional positions. The company posted EBIT margin of -34.5% and negative ROIC of -22%, reflecting profitability pressure despite strong revenue growth. Missed Q2 expectations or reduced 2026 guidance could trigger gap-down breakdowns through support. Medical device sector sentiment and healthcare policy changes remain tail risks.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.